132 related articles for article (PubMed ID: 11454464)
1. A short synthesis of argatroban. a potent selective thrombin inhibitor.
Cossy J; Belotti D
Bioorg Med Chem Lett; 2001 Aug; 11(15):1989-92. PubMed ID: 11454464
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of monomeric and polymeric conjugates carrying a thrombin inhibitor through an ester bond.
Noguchi H; Iwata H; Ikada Y
J Biomed Mater Res; 1998 Mar; 39(4):621-9. PubMed ID: 9492224
[TBL] [Abstract][Full Text] [Related]
3. The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.
Baettig U; Brown L; Brundish D; Dell C; Furzer A; Garman S; Janus D; Kane PD; Smith G; Walker CV; Cockcroft X; Ambler J; Mitchelson A; Talbot MD; Tweed M; Wills N
Bioorg Med Chem Lett; 2000 Jul; 10(14):1563-6. PubMed ID: 10915051
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency.
Brundish D; Bull A; Donovan V; Fullerton JD; Garman SM; Hayler JF; Janus D; Kane PD; McDonnell M; Smith GP; Wakeford R; Walker CV; Howarth G; Hoyle W; Allen MC; Ambler J; Butler K; Talbot MD
J Med Chem; 1999 Nov; 42(22):4584-603. PubMed ID: 10579821
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and anti-thrombotic evaluation of some novel fluorinated thrombin inhibitor derivatives.
Chen H; Ren Y
Arch Pharm (Weinheim); 2015 Jun; 348(6):408-20. PubMed ID: 25881141
[TBL] [Abstract][Full Text] [Related]
7. Argatroban and inhibition of the vasomotor actions of thrombin.
Winn MJ; Jain K; Ku DD
J Cardiovasc Pharmacol; 1993 Nov; 22(5):754-60. PubMed ID: 7506329
[TBL] [Abstract][Full Text] [Related]
8. The thrombin inhibitor argatroban does not influence the endothelium-dependent relaxant and contractile responses of isolated rabbit carotid arteries.
Schrödter HM; Glusa E
Exp Toxicol Pathol; 2003 Jun; 54(5-6):499-504. PubMed ID: 12877364
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors.
Li M; Ren Y
Arch Pharm (Weinheim); 2015 May; 348(5):353-65. PubMed ID: 25824648
[TBL] [Abstract][Full Text] [Related]
10. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
11. Synthetic selective inhibitors of thrombin.
Okamoto S; Hijikata-Okunomiya A
Methods Enzymol; 1993; 222():328-40. PubMed ID: 8412802
[No Abstract] [Full Text] [Related]
12. Inhibitory effect of argatroban on thrombin-induced MAP kinase activation.
Hijikata-Okunomiya A; Nakaya Y; Takahashi A; Inoue N; Taniguchi T; Ishikawa Y
Thromb Haemost; 1998 Sep; 80(3):528-9. PubMed ID: 9759645
[No Abstract] [Full Text] [Related]
13. Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells.
Hijikata-Okunomiya A; Nakaya Y; Inoue N; Takahashi A; Taniguchi T; Wanaka K; Tsuda Y; Okada Y; Ishikawa Y
Thromb Res; 2000 Feb; 97(4):257-62. PubMed ID: 10674413
[No Abstract] [Full Text] [Related]
14. The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Asanuma K; Wakabayashi H; Okamoto T; Asanuma Y; Akita N; Yoshikawa T; Hayashi T; Matsumine A; Uchida A; Sudo A
Breast Cancer; 2013 Jul; 20(3):241-6. PubMed ID: 22359194
[TBL] [Abstract][Full Text] [Related]
15. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.
Asanuma K; Wakabayashi H; Hayashi T; Okuyama N; Seto M; Matsumine A; Kusuzaki K; Suzuki K; Uchida A
Oncology; 2004; 67(2):166-73. PubMed ID: 15539922
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
[TBL] [Abstract][Full Text] [Related]
17. Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Asanuma K; Yoshikawa T; Yoshida K; Okamoto T; Asanuma Y; Hayashi T; Akita N; Oi T; Nishimura A; Hasegawa M; Sudo A
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):27-32. PubMed ID: 27262798
[TBL] [Abstract][Full Text] [Related]
18. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
19. Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Aliter KF; Al-Horani RA
Cardiovasc Drugs Ther; 2021 Apr; 35(2):195-203. PubMed ID: 32870433
[TBL] [Abstract][Full Text] [Related]
20. Combined administration of aspirin and a specific thrombin inhibitor in man.
Clarke RJ; Mayo G; FitzGerald GA; Fitzgerald DJ
Circulation; 1991 May; 83(5):1510-8. PubMed ID: 2022012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
